KRAS and cancer: Based on TCGA pan-cancer data, the percentages of co-mutation of KRAS and TP53 remained highest in PAAD (54%), followed by rectal (31%) and colon (26%) adenocarcinoma and uterine carcinosarcoma (12%) [105].